EntryPoint Capital LLC Acquires Shares of 12,115 Catalyst Pharmaceuticals, Inc. $CPRX

Key Points

• EntryPoint Capital LLC has acquired a new stake in Catalyst Pharmaceuticals, purchasing 12,115 shares valued at approximately $294,000 in the first quarter.
• Several other institutional investors also increased their stakes in Catalyst Pharmaceuticals, with 79.22% of the stock now owned by hedge funds and institutional investors.
• Recent analyst ratings indicate a mix of sentiment, with Zacks and Wall Street Zen downgrading their ratings to a "hold", while Cantor Fitzgerald upgraded to a "strong-buy".

EntryPoint Capital LLC acquired a new stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 12,115 shares of the biopharmaceutical company's stock, valued at approximately $294,000.

Other hedge funds have also recently made changes to their positions in the company. Park Square Financial Group LLC purchased a new position in shares of Catalyst Pharmaceuticals during the fourth quarter valued at approximately $29,000. Sound Income Strategies LLC purchased a new stake in Catalyst Pharmaceuticals during the first quarter valued at approximately $64,000. GAMMA Investing LLC increased its holdings in Catalyst Pharmaceuticals by 26.2% during the first quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company's stock valued at $68,000 after buying an additional 579 shares during the last quarter. Quarry LP purchased a new stake in Catalyst Pharmaceuticals during the fourth quarter valued at approximately $104,000. Finally, New Vernon Capital Holdings II LLC purchased a new stake in Catalyst Pharmaceuticals during the fourth quarter valued at approximately $122,000. 79.22% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Catalyst Pharmaceuticals

In related news, insider Preethi Sundaram sold 2,324 shares of the company's stock in a transaction on Tuesday, June 10th. The shares were sold at an average price of $26.41, for a total transaction of $61,376.84. Following the completion of the transaction, the insider owned 42,681 shares in the company, valued at approximately $1,127,205.21. This represents a 5.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 10.40% of the company's stock.

Catalyst Pharmaceuticals Stock Performance

Shares of NASDAQ CPRX traded down $0.46 during midday trading on Monday, reaching $20.62. The stock had a trading volume of 1,750,775 shares, compared to its average volume of 1,450,354. The stock has a 50-day moving average of $21.23 and a 200-day moving average of $22.58. The company has a market capitalization of $2.52 billion, a price-to-earnings ratio of 12.50, a price-to-earnings-growth ratio of 0.86 and a beta of 0.70. Catalyst Pharmaceuticals, Inc. has a 12-month low of $19.00 and a 12-month high of $26.58.

Wall Street Analyst Weigh In

A number of brokerages have commented on CPRX. Wall Street Zen cut shares of Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Saturday, August 9th. Zacks Research cut shares of Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 19th. Finally, Cantor Fitzgerald raised shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Thursday, June 5th. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $33.20.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.